Mice with a targeted deletion of p53 in myeloid cells selectively lost the Ly6c+CD103+ population and became unresponsive to immunotherapy and immunogenic chemotherapy, supporting that p53 drives differentiation of monocytic precursor cells into dendritic cells and macrophages for cross-presentation of tumor antigens (Sharma et al., 2018). This evidence concerns the gene TP53 and neoplasm.